BioSpace News Archive

Avivagen Inc. is pleased to announce that its scientific team has just published a peer-reviewed paper describing the discovery, natural occurrence, scientific significance, commercial livestock applications and safety of OxBC, the active ingredient of OxC-beta™ Livestock.

Repare Therapeutics Inc. today announced that the Company has received an approximately $1.5 million (¥200 million) research service payment from Ono Pharmaceutical Co., Ltd. (“Ono”).

Bellicum Pharmaceuticals, Inc. today announced that an abstract on early results from a Phase 1 clinical trial for BPX-601, its lead GoCAR-T ® product candidate, has been accepted for poster presentation at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).

Sunshine Biopharma Inc. today announced its board of directors has authorized a share repurchase program to acquire up to $2 million of the Company’s common stock.

iSpecimen Inc. today announced that Tracy Curley, CEO of iSpecimen, will participate in the Healthcare IT Virtual Conference hosted by Maxim Group and M-Vest on Wednesday, January 25, 2023.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its targets to reduce greenhouse gas (GHG) emissions have been approved by the Science Based Targets initiative (SBTi), providing external validation of the Company’s ambitious commitments to minimize its environmental footprint.

AVAIL SCIENTIFIC (OTC PINK: MOBO ) is pleased to announce it is entering into a letter of intent (LOI) to acquire Florida based Relai Neuro LLC which provides Neurological testing and data management.

Zhongchao Inc. today announced that Zhongxin Medical Technology Co., Ltd. (“Zhongxin”), one of the China operating entities of which the Company consolidates the financial results with through certain contractual arrangements, launched the Medication Management Assistance Mini Program on WeChat.

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group,announced today that the first patient was dosed in its Phase 2 AURELIO-05 combination trial of nanrilkefusp alfa (previously known as SOT101), an IL-15 superagonist, and cetuximab in patients with colorectal cancer.

The New York Genome Center announced the launch of the MacMillan Center for the Study of the Non-Coding Cancer Genome, a major new initiative in cancer research to study the role and function of the non-coding genome and epigenome in the evolution, progression, and treatment of multiple cancer types, including breast, ovary, pancreas, gastrointestinal, lung, and hematologic cancers.